Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441566 in mild to moderate psoriasis
NCT05453942Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing SAR441566 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events up to 69 days. Started Jul 2022; status: completed.
02
Drugs
balinatunfib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05453942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453942.